Sohail Ahmed, MD
Infectious Disease · Rockwall, TXNPI 1104866045
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $213 of the $256 with a category attached, or 83.1%. 5 manufacturers reported payments, led by Smith+Nephew at 44.4% of the total. That places this record below the midpoint for infectious disease clinicians in TX, where the typical reported total is $451.
Across 14 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$114
- Merck$78
- Organogenesis Inc.$26
- AbbVie$23
- Viiv Healthcare Company$15
Across 9 payments — averaging $11,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$106K
- Bristol Myers Squibb$313
- E.r. Squibb & Sons, L.L.C.$148
What the payments were for
- Food & beverage$21383%
- Education$4317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 6 | $114 |
| Merck | 5 | $78 |
| Organogenesis Inc. | 1 | $26 |
| AbbVie | 1 | $23 |
| Viiv Healthcare Company | 1 | $15 |
How this compares
$256 in reported general payments places this provider in the 40th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 65 | $18,686 |
| ErtapenemErtapenem Sodium | 68 | $18,645 |
| Vancomycin Hcl-0.9% NaclVancomycin/0.9 % Sod Chloride | 21 | $4,755 |
| Cefepime Hcl | 42 | $4,192 |
| Vancomycin Hcl | 48 | $3,895 |
| Meropenem | 35 | $2,923 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $2,414 |
| CeftriaxoneCeftriaxone Sodium | 39 | $1,793 |
| Cefazolin Sodium | 14 | $492 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Rockwall
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.